NO143741C - Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien - Google Patents

Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien

Info

Publication number
NO143741C
NO143741C NO2724/73A NO272473A NO143741C NO 143741 C NO143741 C NO 143741C NO 2724/73 A NO2724/73 A NO 2724/73A NO 272473 A NO272473 A NO 272473A NO 143741 C NO143741 C NO 143741C
Authority
NO
Norway
Prior art keywords
prostagland
connections
series
preparation
physiologically active
Prior art date
Application number
NO2724/73A
Other languages
English (en)
Norwegian (no)
Other versions
NO143741B (no
Inventor
Michael Ross Johnson
Hans-Jurgen Ernst Hess
Thomas Ken Schaaf
Jasjit Singh Bindra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to NO751726A priority Critical patent/NO751726L/no
Publication of NO143741B publication Critical patent/NO143741B/no
Publication of NO143741C publication Critical patent/NO143741C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056Esters of arylalkanephosphonic acids
    • C07F9/4059Compounds containing the structure (RY)2P(=X)-(CH2)n-C(=O)-(CH2)m-Ar, (X, Y = O, S, Se; n>=1, m>=0)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B63SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
    • B63BSHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING 
    • B63B2211/00Applications
    • B63B2211/02Oceanography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
NO2724/73A 1972-07-13 1973-07-03 Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien NO143741C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO751726A NO751726L (es) 1972-07-13 1975-05-15

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27122072A 1972-07-13 1972-07-13

Publications (2)

Publication Number Publication Date
NO143741B NO143741B (no) 1980-12-29
NO143741C true NO143741C (no) 1981-04-08

Family

ID=23034697

Family Applications (2)

Application Number Title Priority Date Filing Date
NO2724/73A NO143741C (no) 1972-07-13 1973-07-03 Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien
NO743492A NO144830C (no) 1972-07-13 1974-09-26 Substituert cyklopentanderivat for anvendelse som mellomprodukt ved fremstilling av en fysiologisk aktiv prostaglandinforbindelse av e- eller f-serien

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO743492A NO144830C (no) 1972-07-13 1974-09-26 Substituert cyklopentanderivat for anvendelse som mellomprodukt ved fremstilling av en fysiologisk aktiv prostaglandinforbindelse av e- eller f-serien

Country Status (25)

Country Link
JP (4) JPS5241257B2 (es)
AR (2) AR209064A1 (es)
AT (1) AT367033B (es)
BE (1) BE802231A (es)
CA (1) CA1041495A (es)
CH (1) CH593254A5 (es)
CS (1) CS201027B2 (es)
DD (2) DD116459A5 (es)
DE (1) DE2334945A1 (es)
ES (4) ES416865A1 (es)
FI (1) FI57583C (es)
FR (1) FR2192834B1 (es)
GB (1) GB1446341A (es)
HU (4) HU172058B (es)
IE (1) IE37909B1 (es)
IL (2) IL42691A (es)
IN (1) IN138789B (es)
LU (1) LU68015A1 (es)
NL (1) NL7309792A (es)
NO (2) NO143741C (es)
PH (1) PH11461A (es)
SE (3) SE7705946L (es)
SU (4) SU644384A3 (es)
YU (1) YU187773A (es)
ZA (1) ZA734769B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1386146A (en) * 1972-05-03 1975-03-05 Ici Ltd Cyclopentane derivatives
DE2416193C2 (de) 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
DE2463432C2 (es) * 1974-04-03 1987-06-19 Hoechst Ag, 6230 Frankfurt, De
ZA747723B (en) * 1974-12-11 1976-11-24 Pfizer 11-desoxy-15-substituted-omega-pentanor prostaglandins
US4149006A (en) * 1977-01-24 1979-04-10 G. D. Searle & Co. Prostaglandin derivatives having alkynyl, hydroxy and aryloxy junctions in the 2β side chain
GB8329559D0 (en) * 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
SE9002596D0 (sv) * 1990-08-08 1990-08-08 Pharmacia Ab A method for synthesis of prostaglandin derivatives
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
KR100578616B1 (ko) * 2004-07-23 2006-05-10 한미약품 주식회사 D-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
RU2730520C2 (ru) * 2013-12-13 2020-08-24 Аллерган, Инк. Твердые формы альфа, омега дизамещенного дигидроксициклопентильного соединения и способы их получения и применения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1324737A (en) * 1970-11-02 1973-07-25 Upjohn Co Prostaglandins and the preparation thereof
GB1386146A (en) * 1972-05-03 1975-03-05 Ici Ltd Cyclopentane derivatives
IL42373A (en) * 1972-06-02 1977-08-31 Pfizer Oxaprostagliandins and their preparation

Also Published As

Publication number Publication date
NO743492L (no) 1974-01-15
SE7705947L (sv) 1977-05-20
SU584791A3 (ru) 1977-12-15
FI57583C (fi) 1980-09-10
AR214383A1 (es) 1979-06-15
ES437038A1 (es) 1977-01-01
FR2192834B1 (es) 1979-04-06
ZA734769B (en) 1974-06-26
ES437039A1 (es) 1977-01-01
ES416865A1 (es) 1976-03-01
FR2192834A1 (es) 1974-02-15
JPS5297958A (en) 1977-08-17
DD109210A5 (es) 1974-10-20
SU645563A3 (ru) 1979-01-30
JPS5241257B2 (es) 1977-10-17
IE37909L (en) 1974-01-13
IL42691A (en) 1979-07-25
AR209064A1 (es) 1977-03-31
HU171158B (hu) 1977-11-28
ES437037A1 (es) 1977-01-01
IL50308A0 (en) 1976-10-31
IN138789B (es) 1976-04-03
IL42691A0 (en) 1973-10-25
FI57583B (fi) 1980-05-30
HU171156B (hu) 1977-11-28
SU645564A3 (ru) 1979-01-30
NO143741B (no) 1980-12-29
SU644384A3 (ru) 1979-01-25
IE37909B1 (en) 1977-11-09
AU5778473A (en) 1975-01-09
CH593254A5 (es) 1977-11-30
NL7309792A (es) 1974-01-15
JPS4992053A (es) 1974-09-03
DD116459A5 (es) 1975-11-20
ATA620773A (de) 1981-10-15
SE7705945L (sv) 1977-05-20
YU187773A (en) 1982-02-25
PH11461A (en) 1978-02-01
JPS52122349A (en) 1977-10-14
CS201027B2 (en) 1980-10-31
DE2334945A1 (de) 1974-03-07
GB1446341A (en) 1976-08-18
NO144830C (no) 1981-11-18
BE802231A (fr) 1974-01-14
HU171946B (hu) 1978-04-28
AT367033B (de) 1982-05-25
LU68015A1 (es) 1974-01-21
SE7705946L (sv) 1977-05-20
CA1041495A (en) 1978-10-31
NO144830B (no) 1981-08-10
JPS5293753A (en) 1977-08-06
HU172058B (hu) 1978-05-28

Similar Documents

Publication Publication Date Title
SE407579B (sv) Forfarande for framstellning av n-fosfonometylglycin
NO138335C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkanolaminer
NO143575C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive prostansyre-derivater
NO140731C (no) Fremgangsmaate for fremstilling av dimetyleter
SE395149B (sv) Forfarande for framstellning av dibenso-tiepinylpiperazinderivat
SE401676B (sv) Forfarande for framstellning av dibensofuranderivat
SE382053B (sv) Forfarande for framstellning av bifenylylalkanoylaminopyridiner
NO143741C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien
DE2143628B2 (de) Kuenstliche herzkammer und herzhilfe
SE383151B (sv) Forfarande for framstellning av 1-hydroxi-2-pyridoner
SE416176B (sv) Forfarande for framstellning av hogdoserade autibiotikatabletter
SE7600889L (sv) Forfarande for framstellning av deoxo- och dideoxoprostaglandin-e1
SE393111B (sv) Forfarande for framstellning av d-2-halogen-6-metyl-8-substituerad - ergolin
SE380272B (sv) Forfarande for framstellning av n-fosfonmetylglycin
SE396385B (sv) Forfarande for framstellning av n-benshydryl-n'-p-hydroxibensyl-piperaziner
SE399557B (sv) Forfarande for framstellning av tiantren-, tioxanten- och fenoxatiinderivat
FI56830B (fi) Foerfarande foer framstaellning av asparaginylgrupper innehaollande biologiskt aktiva polypeptider
SE415355B (sv) Forfarande for framstellning av fosfonotioureider
SE393808B (sv) Forfarande for framstellning av isomaltit
NO139050C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nororipavin- og tebainderivater
SE391717B (sv) Forfarande for framstellning av 4-aryl-5-aminoalkyl-4-oxazolin-2-oner
SE380805B (sv) Forfarande for framstellning av oxazoler
SE389862B (sv) Forfarande for framstellning av alfa-6-deoxitetracykliner
NO139086C (no) R fremgangsmaate for fremstilling av benzensulfonylurinstoffe
NO137998C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tebain- og oripavin-derivater